Oxford Immunotec Global PLC Announces Appointment of Herm Rosenman to the Board of Directors

OXFORD, United Kingdom and MARLBOROUGH, Mass., Dec. 2, 2013 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company") announced today that Herman ("Herm") Rosenman has been appointed as a member of the Company's Board of Directors and will serve as Chairman of the Board's Audit Committee. Mr. Rosenman served most recently as Senior Vice President, Finance and Chief Financial Officer of Gen-Probe Incorporated, a publicly traded molecular diagnostics company, which was acquired by Hologic, Inc. in 2012. He is currently a member of the Board of Directors and Audit Committee Chairman of Vivus, Inc., a publicly traded biopharmaceutical company, Medistem, Inc., a stem cell therapy company, and BioFire Diagnostics, Inc., a molecular diagnostics company. "Herm brings significant experience to our Board of Directors based upon his past positions as both a senior executive and a director of companies in the diagnostics and healthcare sectors," commented Peter Wrighton-Smith, Ph.D., the Company's Chief Executive Officer. "We are delighted to have Herm join the Board and look forward to working with him to build the Company."

Notes to Editors:

About Oxford Immunotec Global PLC

Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company committed to improving patient care by providing advanced, innovative tests in the field of immunology. Its proprietary T-SPOT technology platform allows it to measure the responses of specific immune cells, known as T cells, to inform the diagnosis, prognosis and monitoring of patients with immunologically controlled diseases. T cells are a central component of the human body's immune system, and are implicated in the control and progression of many medical conditions, including certain types of infectious diseases, cancers and autoimmune diseases. Oxford Immunotec Global PLC is headquartered near Oxford, UK and in Marlborough, MA.

Website: www.oxfordimmunotec.com

Media RelationsBeth ElkinsOxford Immunotec Global PLC+44 1235 442780belkins@oxfordimmunotec.com

Investor RelationsRichard M. AltieriOxford Immunotec Global PLCChief Financial Officer+1 508-481-4648raltieri@oxfordimmunotec.com
 

Posted: December 2013


View comments

Hide
(web4)